Darvoni 60 mg+400 mg is a Product of the Generic Daclatasvir + Sofosbuvir

Darvoni 60 mg+400 mg belongs to the generic category of Daclatasvir + Sofosbuvir. This medicine should be used according to a doctor's advice. We have provided detailed information about the uses, dosage, effectiveness, side effects, precautions, drug interactions, storage conditions, and other important details of Darvoni 60 mg+400 mg. Our goal is to present essential medicine information in one place for patients, caregivers, and healthcare professionals. To better understand Daclatasvir + Sofosbuvir and ensure the safe use of this medicine, please read the information below carefully and consult a healthcare professional when necessary.

Description of Darvoni 60 mg+400 mg

Darvoni 60 mg+400 mg may be available as a prescription or over-the-counter medicine, depending on local regulations and medical recommendations. It is used for the treatment and management of specific conditions or symptoms. The way this medicine is used may vary depending on the patient's condition and the advice of a healthcare provider. Detailed information about the approved uses, therapeutic applications, and other relevant details of Darvoni 60 mg+400 mg is provided below to help users gain a clear understanding of this medicine.

What Is Darvoni 60 mg+400 mg Indications and Uses?

Sofosbuvir directly targets the Hepatitis C virus to stop it from making copies of itself in the liver. Sofosbuvir attaches itself to the genetic information, called RNA, to block the virus from multiplying. And Daclatasvir is a direct-acting antiviral agent (DAA) against the hepatitis C virus.

Pharmacology (Source, Chemical and Physical Composition) Of Darvoni 60 mg+400 mg

Sofosbuvir is an inhibitor of the hepatitis C virus (HCV) NS5B ribonucleic acid (RNA)-dependent RNA polymerase, which is essential for viral replication. Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. In a biochemical assay, GS-461203 inhibited the polymerase activity of the recombinant NS5B from HCV genotype 1b, 2a, 3a and 4a with a 50% inhibitory concentration (IC50) value ranging from 0.7-2.6 micrometer. GS-461203 (the active metabolite of sofosbuvir) is not an inhibitor of human deoxyribonucleic acid (DNA) and RNA polymerases, nor an inhibitor of mitochondrial RNA polymerase.Daclatasvir stops HCV viral RNA replication and protein translation by directly inhibiting HCV protein NS5A. NS5A is critical for HCV viral transcription and translation.

Therapeutic Class

Hepatic viral infections (Hepatitis C)

Darvoni 60 mg+400 mg is a Product of the Generic Daclatasvir + Sofosbuvir